Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide in Rheumatoid Arthritis in Germany: I. Selected DMARDs and Patient-Related Costs

Author： Schädlich Peter K.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.4, 2005-01, pp. : 377-393

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide for Rheumatoid Arthritis in Germany: II. The Contribution of Leflunomide to Efficiency

By Schädlich Peter K.  

PharmacoEconomics, Vol. 23, Iss. 4, 2005-01 ,pp. : 395-420

Adis International

Access to resources Recommend Favorite

Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis

By Alldred A.   Emery P.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 1, 2001-01 ,pp. : 125-137

Informa Healthcare

Access to resources Recommend Favorite

Statin Therapy in Rheumatoid Arthritis: A Cost-Effectiveness and Value-of-Information Analysis

By Bansback Nick   Ara Roberta   Ward Sue   Anis Aslam   Choi Hyon K.  

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 25-37

Adis International

Access to resources Recommend Favorite

Leflunomide in Combination Therapy for Rheumatoid Arthritis

By Savage Ruth L.  

Drug Safety, Vol. 33, Iss. 6, 2010-06 ,pp. : 523-526

Adis International

Access to resources Recommend Favorite

The Cost Effectiveness of Infliximab for Severe Treatment-Resistant Rheumatoid Arthritis in the UK

By Barbieri Marco  

PharmacoEconomics, Vol. 23, Iss. 6, 2005-01 ,pp. : 607-618

Adis International

Access to resources Recommend Favorite